Sucampo Pharmaceuticals, Inc.
| Nasdaq: SCMP
Sucampo Pharmaceuticals, Inc. is a global pharmaceutical company. It is focused on innovative research, discovery, development and commercialization of proprietary drugs based on prostones and other novel drug technologies. Prostones, naturally occurring fatty acid metabolites that have emerged as promising compounds with unique physiological activities, can be targeted for the treatment of unmet or underserved medical needs. It is focused on developing and commercializing prostone-based drugs to treat gastrointestinal, ophthalmic, neurologic, and oncology-based inflammatory disorders, and is also considering other potential therapeutic applications of its drug technologies. The company was founded by Ryuji Ueno and Sachiko Kuno on December 5, 1996 and is headquartered in Bethesda, MD.